Depending on the tumor context, IL-33 produced in the TME can activate diverse immune cells which are able to promote a pro-tumor effect such as TAM, MDSC, fibroblasts, mast cells, Treg and DC, or to prevent tumor development such as NK cells, CD8+ T cells, iNKT, ILC2, TH9, and TH17. This evidence concerns the gene CD8A and neoplasm.